Cambridge Healthtech Institute’s 14th Annual
Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Creating the Killer Combo
May 12-13, 2026
Multispecific antibodies are dominating the biologics pipeline and a vast number of novel formats and targeting approaches have been created and are are being tested. While the main application for multispecific antibodies is in oncology, there are a number that are being developed against infectious disease, ocular, inflammatory, autoimmune, neurodegenerative, and vascular indications. Insights into how these molecules are advancing through preclinical and clinical development will be featured by the top experts in the industry. Don’t miss Cambridge Healthtech Institute's 14th annual Advancing Multispecific Antibodies and Combination Therapy to the Clinic conference at PEGS Boston to review the latest results and gain insights into strategies that are bringing successful first-in-class molecules to market.
Coverage will include, but is not limited to:
- Surveying results of multispecifics in preclinical and clinical development
- Reviewing latest approaches for co-stimulatory bispecific antibodies, combination therapy, cell engagers, and beyond
- Advancing constructs with gating, masking, degrader, shuttle, and arming techniques
- Exploring use in non-cancer indications including autoimmune and beyond
- Incorporating pretargeting approaches
- Understanding clinical data from emerging bispecific ADCs
The deadline for priority consideration is October 31, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: